IDEAYA Biosciences, Inc. (IDYA) Earnings Call Transcripts
IDEAYA Biosciences, Inc.'s Latest Earnings Call - April 13, 2026
In the first quarter of fiscal year 2026, IDEAYA Biosciences reported significant advancements in its clinical trial for darovasertib, a treatment for metastatic uveal melanoma. The OptimUM-02 study demonstrated a median progression-free survival (PFS) of 6.9 months compared to 3.1 months in the control arm, with a p-value of less than 0.0001, indicating a strong efficacy signal. While specific revenue and earnings figures were not disclosed, management expressed optimism about the potential for accelerated approval and future commercialization, signaling a positive outlook for the stock.
Reported metrics
| Metric | Value |
|---|---|
| Median PFS | 6.9 months (beat) |
| Overall Response Rate | 37.1% (beat) |
| Hazard Ratio | 0.42 (beat) |
| FDA Designations | Breakthrough Therapy, Fast Track (positive) |
| Patient Enrollment | 313 (neutral) |
| Expected Interim OS Readout | Mid-2027 (neutral) |
Guidance from management
Management is optimistic about the potential for accelerated approval and plans to engage with the FDA regarding the filing timeline. They are focused on advancing darovasertib through various clinical settings.
What management said
Thank you so much, Darrin. This now concludes the prepared remarks. And operator, let's now please transition to the analyst Q&A portion of the webcast. We please ask the analyst keep to question. We will also ask the operator status reach the 30-minute mark. Operator, you may now proceed to the first question.
Yes. And upon the OS question, we will not be specifically at the upcoming medical conference. So as we noted, we have observed an early trend, which is encouraging. There's been about roughly 10 months of follow-up. So to see that early separation, we're quite encouraged. And as you know, we did report a robust survival result back in the fall at the Society of Melanoma Research. With that, Dr. McKean, if you're on ...
What analysts pressed on
Analysts expressed concerns regarding the overall survival data and its impact on the drug's uptake, particularly for HLA-A2 positive patients. There was also inquiry about the potential for dose adjustments due to adverse events.
Main topics on the call
- Clinical Trial Success — The OptimUM-02 trial showed a statistically significant improvement in median PFS of 6.9 months versus 3.1 months in the control arm, with a hazard ratio of 0.42 and a p-value of less than 0.0001. CEO Yujiro Hata noted, ...
- Overall Response Rate — The overall response rate for the darovasertib and crizotinib combination was reported at 37.1%, significantly higher than the 5.8% in the control arm, with a p-value of less than 0.0001. This response rate is a critical...
- Future Trials and Applications — Management indicated ongoing and upcoming trials for darovasertib in both neoadjuvant and adjuvant settings, emphasizing its potential to become a backbone therapy for all phases of uveal melanoma. Dr. Beaupre stated, "w...
- Regulatory Pathway — IDEAYA plans to engage with the FDA for expedited filing options due to the breakthrough therapy designation of darovasertib. Darrin Beaupre mentioned, "we have Fast Track, and we have breakthrough... so I think they're ...
Read the full IDEAYA Biosciences, Inc. transcript (April 13, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. (IDYA) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 32 calls on record spanning March 15, 2022 to September 14, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 32 IDEAYA Biosciences, Inc. earnings call transcripts on record, spanning March 15, 2022 to September 14, 2026. Based on this history, IDEAYA Biosciences, Inc. reports quarterly. The most recent call on file is dated September 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- IDYA
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 32
- First call
- March 15, 2022
- Most recent
- September 14, 2026
- Reporting cadence
- quarterly